Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

data for the first time and an exploratory analysis among patients with bladder primary tumors (muscle-invasive bladder cancer [MIBC]). Consistent DFS benefit with nivolumab versus placebo was ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. The clinical ...

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

In a phase 1 trial in patients with non-muscle invasive bladder cancer, Aura’s viruslike drug conjugate (VDC) bel-sar—along with infrared light activation—completely eradicated the tumors of ...

Metastatic urothelial cancer exhibits substantial molecular heterogeneity compared with the primary tumour, complicating the development of accurate biomarkers. Pre-treatment metastatic biopsies ...

The two most common types are stress urinary incontinence, which may be caused by weakened pelvic floor muscles, and overactive bladder ... together with pelvic muscle exercises.

which is the muscle that lines the bladder. OAB and detrusor overactivity can both cause trouble with urination. With these conditions, you may have involuntary spasms in your bladder muscles ...